Skip to main content
. 2021 Apr 16;5:32. doi: 10.1038/s41698-021-00170-7

Fig. 4. Drug sensitivity profile of the EGFR-L747P mutation using the anti-EGFR-antibody combination therapy.

Fig. 4

a Growth inhibition curve details. EGFR mutant Ba/F3 cells treated with combination therapy of afatinib and cetuximab. After 72 h of drug treatment, cell viability was measured using the CellTiter-Glo assay (n = 3). b Growth inhibition curve details. EGFR mutant Ba/F3 cells treated with a combination therapy of EAI-045 and cetuximab. After 72 h of drug treatment, cell viability was measured using the CellTiter-Glo assay (n = 3). c, d Inhibition of the EGFR signaling pathway in Ba/F3 EGFR mutant cells treated with the combination therapy of afatinib or EAI-045 with cetuximab (10 μg/mL) for 3 h (for afatinib) or 6 h (for EAI-045) was evaluated by western blot with the indicated antibodies.